{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:10:25Z","timestamp":1792800625132,"version":"4.5.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32160223"],"award-info":[{"award-number":["32160223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31860254"],"award-info":[{"award-number":["31860254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31860254"],"award-info":[{"award-number":["31860254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32160223"],"award-info":[{"award-number":["32160223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"General Program of Science and Technology Department of Yunnan Provincial","award":["2018FG001-039"],"award-info":[{"award-number":["2018FG001-039"]}]},{"name":"General Program of Science and Technology Department of Yunnan Provincial","award":["2018FG001-039"],"award-info":[{"award-number":["2018FG001-039"]}]},{"name":"General Program of Science and Technology Department of Yunnan Provincial","award":["2018FG001-039"],"award-info":[{"award-number":["2018FG001-039"]}]},{"name":"Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders of the Department of Science and Technology of Yunnan Province","award":["202105AC160047"],"award-info":[{"award-number":["202105AC160047"]}],"id":[{"id":"https:\/\/ror.org\/04qgr7x96","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Reserve Talents Project for Young and Middle-aged Academic and Technical Leaders of the Department of Science and Technology of Yunnan Province","award":["202105AC160047"],"award-info":[{"award-number":["202105AC160047"]}],"id":[{"id":"https:\/\/ror.org\/04qgr7x96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients are diagnosed with advanced stages of the disease. Unfortunately, the development of drug resistance in tumors leads to relapsed or refractory peripheral T-Cell Lymphomas (r\/r PTCL), resulting in highly unsatisfactory treatment outcomes for these patients. This review provides an overview of potential mechanisms contributing to PTCL treatment resistance, encompassing aspects such as tumor heterogeneity, tumor microenvironment, and abnormal signaling pathways in PTCL development. The existing drugs aimed at overcoming PTCL resistance and their potential resistance mechanisms are also discussed. Furthermore, a summary of ongoing clinical trials related to PTCL is presented, with the aim of aiding clinicians in making informed treatment decisions.<\/jats:p>","DOI":"10.1186\/s12943-023-01904-w","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:02:31Z","timestamp":1704337351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Therapeutic challenges in peripheral T-cell lymphoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yunpeng","family":"Luan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinzuo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shili","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"1","key":"1904_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5581\/1516-8484.20120013","volume":"34","author":"M Bellei","year":"2011","unstructured":"Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, Souza CAD, Gab\u00fas R, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M. T-Cell Lymphomas in South America and Europe. Rev Bras Hematol Hemoter. 2011;34(1):42\u20137. https:\/\/doi.org\/10.5581\/1516-8484.20120013.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"20","key":"1904_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"key":"1904_CR3","doi-asserted-by":"publisher","first-page":"1099265","DOI":"10.3389\/fonc.2022.1099265","volume":"12","author":"C Murga-Zamalloa","year":"2022","unstructured":"Murga-Zamalloa C, Inamdar K. Classification and Challenges in the Histopathological Diagnosis of Peripheral T-Cell Lymphomas, Emphasis on the WHO-HAEM5 Updates. Front Oncol. 2022;12:1099265. https:\/\/doi.org\/10.3389\/fonc.2022.1099265.","journal-title":"Front Oncol"},{"issue":"3","key":"1904_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1046\/j.1365-2141.2000.01988.x","volume":"109","author":"AC Aisenberg","year":"2000","unstructured":"Aisenberg AC. Historical review of lymphomas: historical review. Br J Haematol. 2000;109(3):466\u201376. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01988.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"1904_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/cancers15030589","volume":"15","author":"R Stuver","year":"2023","unstructured":"Stuver R, Moskowitz AJ. Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma. Cancers. 2023;15(3):589. https:\/\/doi.org\/10.3390\/cancers15030589.","journal-title":"Cancers"},{"issue":"20","key":"1904_CR6","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-14-2020","volume":"20","author":"OA O\u2019Connor","year":"2014","unstructured":"O\u2019Connor OA, Bhagat G, Ganapathi K, Pedersen MB, D\u2019Amore F, Radeski D, Bates SE. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clin Cancer Res. 2014;20(20):5240\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2020.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1904_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of Peripheral T-Cell Lymphomas in a Single North American Institution by the WHO Classification. Ann Oncol. 2004;15(10):1467\u201375. https:\/\/doi.org\/10.1093\/annonc\/mdh392.","journal-title":"Ann Oncol"},{"key":"1904_CR8","unstructured":"Bachow SH, O'Connor OA. Emerging therapies in relapsed and refractory peripheral T-cell lymphoma. Clin Adv Hematol Oncol. 2015;13(12):837\u201346."},{"issue":"11","key":"1904_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s11912-022-01310-3","volume":"24","author":"NC Foley","year":"2022","unstructured":"Foley NC, Mehta-Shah N. Management of peripheral T-cell lymphomas and the role of transplant. Curr Oncol Rep. 2022;24(11):1489\u201399. https:\/\/doi.org\/10.1007\/s11912-022-01310-3.","journal-title":"Curr Oncol Rep"},{"issue":"7782","key":"1904_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1.","journal-title":"Nature"},{"issue":"9","key":"1904_CR11","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. IJMS. 2020;21(9):3233. https:\/\/doi.org\/10.3390\/ijms21093233.","journal-title":"IJMS"},{"key":"1904_CR12","doi-asserted-by":"publisher","unstructured":"Alaggio R,  Amador C,  Anagnostopoulos I,  Attygalle AD, Araujo IBDO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng W-J, Choi JK, Chuang S-S, Coupland SE, Czader M, Dave SS, De Jong D, Du M-Q, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li X-Q, Lim MS, Liu W-P, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng S-B, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"3","key":"1904_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/PPO.0000000000000452","volume":"26","author":"WB Pearse","year":"2020","unstructured":"Pearse WB, Pro B. Diagnosis, risk stratification, and treatment of peripheral T-Cell Lymphomas: past and present. Cancer J. 2020;26(3):253\u20139. https:\/\/doi.org\/10.1097\/PPO.0000000000000452.","journal-title":"Cancer J"},{"issue":"1","key":"1904_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse E, Zhao W-L, Xiong J, Kwong Y-L. How we treat NK\/T-Cell lymphomas. J Hematol Oncol. 2022;15(1):74. https:\/\/doi.org\/10.1186\/s13045-022-01293-5.","journal-title":"J Hematol Oncol"},{"key":"1904_CR15","doi-asserted-by":"publisher","unstructured":"Wang, X.; Wang, W.; Vega, F.; Quesada, A. E. Aggressive Mediastinal Lymphomas. Semin Diagn Pathol 2021, S0740257021000496. https:\/\/doi.org\/10.1053\/j.semdp.2021.06.010.","DOI":"10.1053\/j.semdp.2021.06.010"},{"issue":"3","key":"1904_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1309\/AJCPMF03LVSBLHPJ","volume":"144","author":"MJ You","year":"2015","unstructured":"You MJ, Medeiros LJ, Hsi ED. T-Lymphoblastic Leukemia\/Lymphoma. Am J Clin Pathol. 2015;144(3):411\u201322. https:\/\/doi.org\/10.1309\/AJCPMF03LVSBLHPJ.","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"1904_CR17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/biomedicines9111621","volume":"9","author":"P Shiraz","year":"2021","unstructured":"Shiraz P, Jehangir W, Agrawal V. T-cell acute lymphoblastic leukemia\u2014current concepts in molecular biology and management. Biomedicines. 2021;9(11):1621. https:\/\/doi.org\/10.3390\/biomedicines9111621.","journal-title":"Biomedicines"},{"key":"1904_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2020.00273","volume":"10","author":"B Fattizzo","year":"2020","unstructured":"Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The Physiopathology of T- Cell acute lymphoblastic leukemia: focus on molecular aspects. Front Oncol. 2020;10:273. https:\/\/doi.org\/10.3389\/fonc.2020.00273.","journal-title":"Front Oncol"},{"issue":"8","key":"1904_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16(8):494\u2013507. https:\/\/doi.org\/10.1038\/nrc.2016.63.","journal-title":"Nat Rev Cancer"},{"key":"1904_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2147\/IJGM.S294715","volume":"14","author":"X Xu","year":"2021","unstructured":"Xu X, Zhai Q, Jin H, Yu Y, Han D, Zhang H, Fu K, Meng B. SET-NUP214 fusion gene involved early T-cell precursor acute lymphoblastic leukemia in adult with B marker expression. IJGM. 2021;14:659\u201364. https:\/\/doi.org\/10.2147\/IJGM.S294715.","journal-title":"IJGM"},{"issue":"30","key":"1904_CR21","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1038\/onc.2015.462","volume":"35","author":"M Tesio","year":"2016","unstructured":"Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogenic PTEN functions and models in T-cell malignancies. Oncogene. 2016;35(30):3887\u201396. https:\/\/doi.org\/10.1038\/onc.2015.462.","journal-title":"Oncogene"},{"issue":"15","key":"1904_CR22","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairism\u00e4gi M-L, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d\u2019Amore F, Inghirami G, Bertoni F, De Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376. https:\/\/doi.org\/10.1182\/blood-2018-09-872549.","journal-title":"Blood"},{"issue":"7380","key":"1904_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen S-C, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui C-H, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157\u201363. https:\/\/doi.org\/10.1038\/nature10725.","journal-title":"Nature"},{"issue":"8","key":"1904_CR24","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1128\/JVI.78.8.4108-4119.2004","volume":"78","author":"ED Cahir-McFarland","year":"2004","unstructured":"Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E. Role of NF-\u03baB in cell survival and transcription of latent membrane protein 1-expressing or epstein-barr virus latency III-infected cells. J Virol. 2004;78(8):4108\u201319. https:\/\/doi.org\/10.1128\/JVI.78.8.4108-4119.2004.","journal-title":"J Virol"},{"issue":"3","key":"1904_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.pathol.2022.12.350","volume":"55","author":"M Parilla","year":"2023","unstructured":"Parilla M, Quesada AE, Medeiros LJ, Thakral B. An update on genetic aberrations in T-cell neoplasms. Pathology. 2023;55(3):287\u2013301. https:\/\/doi.org\/10.1016\/j.pathol.2022.12.350.","journal-title":"Pathology"},{"issue":"1","key":"1904_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pathol.2019.09.011","volume":"52","author":"SS-S Hue","year":"2020","unstructured":"Hue SS-S, Oon ML, Wang S, Tan S-Y, Ng S-B. Epstein-barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. Pathology. 2020;52(1):111\u201327. https:\/\/doi.org\/10.1016\/j.pathol.2019.09.011.","journal-title":"Pathology"},{"issue":"2","key":"1904_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3324\/haematol.2017.180430","volume":"103","author":"S-B Ng","year":"2018","unstructured":"Ng S-B, Chung T-H, Kato S, Nakamura S, Takahashi E, Ko Y-H, Khoury JD, Yin CC, Soong R, Jeyasekharan AD, Hoppe MM, Selvarajan V, Tan S-Y, Lim S-T, Ong C-K, Nairism\u00e4gi M-L, Maheshwari P, Choo S-N, Fan S, Lee C-K, Chuang S-S, Chng W-J. Epstein-barr virus-associated primary nodal T\/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2018;103(2):278\u201387. https:\/\/doi.org\/10.3324\/haematol.2017.180430.","journal-title":"Haematologica"},{"key":"1904_CR28","doi-asserted-by":"publisher","unstructured":"Shafiee, A.; Shamsi, S.; Kohandel Gargari, O.; Beiky, M.; Allahkarami, M. M.; Miyanaji, A. B.; Aghajanian, S.; Mozhgani, S. EBV Associated T\u2010 and NK\u2010cell lymphoproliferative diseases: a comprehensive overview of clinical manifestations and novel therapeutic insights. Rev Med Virol. 2022, 32 (4). https:\/\/doi.org\/10.1002\/rmv.2328.","DOI":"10.1002\/rmv.2328"},{"issue":"3","key":"1904_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui B-W, Wang N, Dai Y-T, Zhang H, Wang C-F, Zhong H-J, Cheng S, Ou-Yang B-S, Hu Y, Zhang X, Xu B, Qian W-B, Tao R, Yan F, Hu J-D, Hou M, Ma X-J, Wang X, Liu Y-H, Zhu Z-M, Huang X-B, Liu L, Wu C-Y, Huang L, Shen Y-F, Huang R-B, Xu J-Y, Wang C, Wu D-P, Yu L, Li J-F, Xu P-P, Wang L, Huang J-Y, Chen S-J, Zhao W-L. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020;37(3):403-419.e6. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.005.","journal-title":"Cancer Cell"},{"issue":"11","key":"1904_CR30","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL, Nairism\u00e4gi M-L, Laurensia Y, Lim J-Q, Tan J, Li Z-M, Pang W-L, Kizhakeyil A, Wijaya G-C, Huang D-C, Nagarajan S, Chia BK-H, Cheah D, Liu Y-H, Zhang F, Rao H-L, Tang T, Wong EK-Y, Bei J-X, Iqbal J, Grigoropoulos N-F, Ng S-B, Chng W-J, Teh B-T, Tan S-Y, Verma NK, Fan H, Lim S-T, Ong C-K. Oncogenic Activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood. 2018;132(11):1146\u201358. https:\/\/doi.org\/10.1182\/blood-2018-01-829424.","journal-title":"Blood"},{"issue":"1","key":"1904_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/life12010073","volume":"12","author":"H Kim","year":"2022","unstructured":"Kim H, Ko YH. The pathologic and genetic characteristics of extranodal NK\/T-cell lymphoma. Life (Basel). 2022;12(1):73. https:\/\/doi.org\/10.3390\/life12010073.","journal-title":"Life (Basel)"},{"key":"1904_CR32","doi-asserted-by":"publisher","unstructured":"Nasr, R.; Mar\u00e7ais, A.; Hermine, O.; Bazarbachi, A. Overview of Targeted Therapies for Adult T-Cell Leukemia\/Lymphoma. In Human T-Lymphotropic Viruses; Casoli, C., Ed.; Methods in Molecular Biology; Springer New York: New York. 2017; 1582: 197\u2013216. https:\/\/doi.org\/10.1007\/978-1-4939-6872-5_15.","DOI":"10.1007\/978-1-4939-6872-5_15"},{"issue":"1","key":"1904_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/gcc.22313","volume":"55","author":"A Stengel","year":"2016","unstructured":"Stengel A, Kern W, Zenger M, Perglerov\u00e1 K, Schnittger S, Haferlach T, Haferlach C. Genetic Characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker: comprehensive genetic characterization of T-PLL. Genes Chromosomes Cancer. 2016;55(1):82\u201394. https:\/\/doi.org\/10.1002\/gcc.22313.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"1904_CR34","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.3324\/haematol.2018.213512","volume":"104","author":"D Sibon","year":"2019","unstructured":"Sibon D, Nguyen D-P, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Tilly H, Jais J-P, Savage KJ. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104(12):e562\u20135. https:\/\/doi.org\/10.3324\/haematol.2018.213512.","journal-title":"Haematologica"},{"issue":"9","key":"1904_CR35","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473\u201380. https:\/\/doi.org\/10.1182\/blood-2014-04-571091.","journal-title":"Blood"},{"key":"1904_CR36","doi-asserted-by":"publisher","unstructured":"Qiu, L.; Tang, G.; Li, S.; Vega, F.; Lin, P.; Wang, S. A.; Wang, W.; Iyer, S. P.; Malpica, L.; Miranda, R. N.; Konoplev, S.; Tang, Z.; Fang, H.; Medeiros, L. J.; Xu, J. DUSP22 Rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematol 2022. https:\/\/doi.org\/10.3324\/haematol.2022.281222.","DOI":"10.3324\/haematol.2022.281222"},{"issue":"5","key":"1904_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","volume":"132","author":"N Oishi","year":"2018","unstructured":"Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, Mai M, Benson HK, Sattler CA, Boddicker RL, McPhail ED, Bennani NN, Harless CA, Singh K, Clemens MW, Medeiros LJ, Miranda RN, Feldman AL. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood. 2018;132(5):544\u20137. https:\/\/doi.org\/10.1182\/blood-2017-12-821868.","journal-title":"Blood"},{"key":"1904_CR38","doi-asserted-by":"publisher","first-page":"1101441","DOI":"10.3389\/fonc.2023.1101441","volume":"13","author":"J Weiss","year":"2023","unstructured":"Weiss J, Reneau J, Wilcox RA. PTCL, NOS: an update on classification, risk-stratification, and treatment. Front Oncol. 2023;13:1101441. https:\/\/doi.org\/10.3389\/fonc.2023.1101441.","journal-title":"Front Oncol"},{"issue":"19","key":"1904_CR39","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, De Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915\u201323. https:\/\/doi.org\/10.1182\/blood-2013-11-536359.","journal-title":"Blood"},{"issue":"10","key":"1904_CR40","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3390\/cancers14102392","volume":"14","author":"A Krug","year":"2022","unstructured":"Krug A, Tari G, Saidane A, Gaulard P, Ricci J-E, Lemonnier F, Verhoeyen E. Novel T follicular helper-like T-cell lymphoma therapies: from preclinical evaluation to clinical reality. Cancers (Basel). 2022;14(10):2392. https:\/\/doi.org\/10.3390\/cancers14102392.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1904_CR41","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095\u2013102. https:\/\/doi.org\/10.1182\/blood-2016-09-692541.","journal-title":"Blood"},{"issue":"2","key":"1904_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, Kim M-Y, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370. https:\/\/doi.org\/10.1038\/ng.2873.","journal-title":"Nat Genet"},{"issue":"8","key":"1904_CR43","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","volume":"32","author":"J Steinhilber","year":"2019","unstructured":"Steinhilber J, Mederake M, Bonzheim I, Serins\u00f6z-Linke E, M\u00fcller I, Fallier-Becker P, Lemonnier F, Gaulard P, Fend F, Quintanilla-Martinez L. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. Mod Pathol. 2019;32(8):1123\u201334. https:\/\/doi.org\/10.1038\/s41379-019-0254-4.","journal-title":"Mod Pathol"},{"issue":"52","key":"1904_CR44","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1073\/pnas.1617929114","volume":"113","author":"F Lemonnier","year":"2016","unstructured":"Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, Broutin S, Martin N, Fataccioli V, Pelletier R, Wakeham A, Snow BE, de Leval L, Pujals A, Haioun C, Paci A, Tobin ER, Narayanaswamy R, Yen K, Jin S, Gaulard P, Mak TW. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci U S A. 2016;113(52):15084\u20139. https:\/\/doi.org\/10.1073\/pnas.1617929114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1904_CR45","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.3324\/haematol.2017.186767","volume":"103","author":"D Vallois","year":"2018","unstructured":"Vallois D, Dupuy A, Lemonnier F, Allen G, Missiaglia E, Fataccioli V, Ortonne N, Clavert A, Delarue R, Rousselet M-C, Fabiani B, Llamas-Gutierrez F, Ogawa S, Thome M, Ko YH, Kataoka K, Gaulard P, de Leval L. RNA Fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica. 2018;103(8):e360\u20133. https:\/\/doi.org\/10.3324\/haematol.2017.186767.","journal-title":"Haematologica"},{"issue":"24","key":"1904_CR46","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood.2019003385","volume":"134","author":"A Carbone","year":"2019","unstructured":"Carbone A, Gloghini A. Subclassifying peripheral T-cell lymphoma NOS. Blood. 2019;134(24):2120\u20131. https:\/\/doi.org\/10.1182\/blood.2019003385.","journal-title":"Blood"},{"issue":"7","key":"1904_CR47","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","volume":"66","author":"T Nagato","year":"2017","unstructured":"Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H. Programmed death-Ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66(7):877\u201390. https:\/\/doi.org\/10.1007\/s00262-017-1987-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"1904_CR48","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","volume":"123","author":"T Wang","year":"2014","unstructured":"Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, Ristow K, Habermann TM, Thomas D, Ziesmer SC, Wellik LE, Lanigan TM, Witzig TE, Pittelkow MR, Bailey NG, Hristov AC, Lim MS, Ansell SM, Wilcox RA. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007\u201315. https:\/\/doi.org\/10.1182\/blood-2013-12-544809.","journal-title":"Blood"},{"issue":"13","key":"1904_CR49","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization States in the tumor microenvironment. IJMS. 2021;22(13):6995. https:\/\/doi.org\/10.3390\/ijms22136995.","journal-title":"IJMS"},{"issue":"5","key":"1904_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"A Sica","year":"2008","unstructured":"Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349\u201355. https:\/\/doi.org\/10.1016\/j.semcancer.2008.03.004.","journal-title":"Semin Cancer Biol"},{"key":"1904_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2015.06.001","volume":"34","author":"E Tse","year":"2015","unstructured":"Tse E, Kwong Y-L. T-cell lymphoma: microenvironment-related biomarkers. Semin Cancer Biol. 2015;34:46\u201351. https:\/\/doi.org\/10.1016\/j.semcancer.2015.06.001.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1904_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3109\/10428194.2010.529204","volume":"52","author":"W Zhang","year":"2011","unstructured":"Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma not otherwise specified. Leukemia Lymphoma. 2011;52(1):46\u201352. https:\/\/doi.org\/10.3109\/10428194.2010.529204.","journal-title":"Leukemia Lymphoma"},{"issue":"5","key":"1904_CR53","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1007\/s12032-012-0244-6","volume":"29","author":"Z-X Lin","year":"2012","unstructured":"Lin Z-X, Bai B, Cai Q-C, Cai Q-Q, Wang X-X, Wu X-Y, Huang H-Q. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol. 2012;29(5):3522\u20138. https:\/\/doi.org\/10.1007\/s12032-012-0244-6.","journal-title":"Med Oncol"},{"issue":"4","key":"1904_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1440-1827.2010.02514.x","volume":"60","author":"D Niino","year":"2010","unstructured":"Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, Kiyasu J, Takeuchi M, Suefuji N, Sugita Y, Takeya M, Ohshima K. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-Cell Lymphoma (AITL). Pathol Int. 2010;60(4):278\u201383. https:\/\/doi.org\/10.1111\/j.1440-1827.2010.02514.x.","journal-title":"Pathol Int"},{"issue":"7","key":"1904_CR55","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/cas.12167","volume":"104","author":"Y Komohara","year":"2013","unstructured":"Komohara Y, Niino D, Saito Y, Ohnishi K, Horlad H, Ohshima K, Takeya M. Clinical Significance of CD 163 + tumor-associated macrophages in patients with adult T-cell leukemia\/lymphoma. Cancer Sci. 2013;104(7):945\u201351. https:\/\/doi.org\/10.1111\/cas.12167.","journal-title":"Cancer Sci"},{"issue":"4","key":"1904_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295\u2013307. https:\/\/doi.org\/10.1038\/nri1806.","journal-title":"Nat Rev Immunol"},{"issue":"5609","key":"1904_CR57","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057\u201361. https:\/\/doi.org\/10.1126\/science.1079490.","journal-title":"Science"},{"issue":"4","key":"1904_CR58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1309\/L65GWEQ803PP6VX1","volume":"130","author":"I Bonzheim","year":"2008","unstructured":"Bonzheim I, Geissinger E, Tinguely M, Roth S, Grieb T, Reimer P, Wilhelm M, Rosenwald A, M\u00fcller-Hermelink HK, R\u00fcdiger T. Evaluation of FoxP3 expression in peripheral T-cell lymphoma. Am J Clin Pathol. 2008;130(4):613\u20139. https:\/\/doi.org\/10.1309\/L65GWEQ803PP6VX1.","journal-title":"Am J Clin Pathol"},{"issue":"13","key":"1904_CR59","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.7314\/APJCP.2015.16.13.5359","volume":"16","author":"MM Shareef","year":"2015","unstructured":"Shareef MM, Elgarhy LH, Wasfy RE-S. Expression of granulysin and FOXP3 in cutaneous T cell lymphoma and s\u00e9zary syndrome. Asian Pac J Cancer Prev. 2015;16(13):5359\u201364. https:\/\/doi.org\/10.7314\/APJCP.2015.16.13.5359.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1904_CR60","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbagen.2013.09.020","volume":"1840","author":"S Kant","year":"2014","unstructured":"Kant S, Kumar A, Singh SM. Tumor Growth Retardation and Chemosensitizing Action of Fatty Acid Synthase Inhibitor Orlistat on T Cell Lymphoma: Implication of Reconstituted Tumor Microenvironment and Multidrug Resistance Phenotype. Biochimica et Biophysica Acta (BBA) - General Subjects. 2014;1840(1):294\u2013302. https:\/\/doi.org\/10.1016\/j.bbagen.2013.09.020.","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"key":"1904_CR61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcancer.2019.08.006","volume":"60","author":"S Nobili","year":"2020","unstructured":"Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. Role of ATP-binding cassette transporters in cancer initiation and progression. Semin Cancer Biol. 2020;60:72\u201395. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.006.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1904_CR62","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/ijms22041593","volume":"22","author":"L Jacobo-Albavera","year":"2021","unstructured":"Jacobo-Albavera L, Dom\u00ednguez-P\u00e9rez M, Medina-Leyte DJ, Gonz\u00e1lez-Garrido A, Villarreal-Molina T. The role of the ATP-Binding Cassette A1 (ABCA1) in human disease. IJMS. 2021;22(4):1593. https:\/\/doi.org\/10.3390\/ijms22041593.","journal-title":"IJMS"},{"issue":"7","key":"1904_CR63","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1101\/gr.184901","volume":"11","author":"M Dean","year":"2001","unstructured":"Dean M, Rzhetsky A, Allikmets R. The human ATP-Binding Cassette (ABC) transporter superfamily. Genome Res. 2001;11(7):1156\u201366. https:\/\/doi.org\/10.1101\/gr.184901.","journal-title":"Genome Res"},{"key":"1904_CR64","doi-asserted-by":"publisher","first-page":"103639","DOI":"10.1016\/j.etap.2021.103639","volume":"85","author":"M Gao","year":"2021","unstructured":"Gao M, Liu L, Zhang X, Li Z, Zhang M. Interleukin-6 reverses Adriamycin resistance in nasal NK\/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2\/STAT3\/NF-\u03baB\/P65 pathway. Environ Toxicol Pharmacol. 2021;85:103639. https:\/\/doi.org\/10.1016\/j.etap.2021.103639.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"9","key":"1904_CR65","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1600-0463.2008.00974.x","volume":"116","author":"A Saglam","year":"2008","unstructured":"Saglam A, Hayran M, Uner AH. Immunohistochemical expression of multidrug resistance proteins in mature T\/NK-cell lymphomas. APMIS. 2008;116(9):791\u2013800. https:\/\/doi.org\/10.1111\/j.1600-0463.2008.00974.x.","journal-title":"APMIS"},{"issue":"5","key":"1904_CR66","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1046\/j.1440-1827.2001.01214.x","volume":"51","author":"CK Jung","year":"2001","unstructured":"Jung CK, Lee KY, Kim Y, Han K, Shim SI, Kim BK, Kang CS. Epstein-barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int. 2001;51(5):355\u201363. https:\/\/doi.org\/10.1046\/j.1440-1827.2001.01214.x.","journal-title":"Pathol Int"},{"issue":"11","key":"1904_CR67","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","volume":"76","author":"M Yamaguchi","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, Shirakawa S, Fukumoto M. Frequent expression of P-Glycoprotein\/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19951201)76:11%3c2351::AID-CNCR2820761125%3e3.0.CO;2-1.","journal-title":"Cancer"},{"issue":"2","key":"1904_CR68","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.V93.2.599","volume":"93","author":"M Egashira","year":"1999","unstructured":"Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-Glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-Glycoprotein function by Cyclosporin A and its analogue, PSC833. Blood. 1999;93(2):599\u2013606.","journal-title":"Blood"},{"issue":"10","key":"1904_CR69","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1038\/s41375-020-0801-5","volume":"34","author":"Q Chen","year":"2020","unstructured":"Chen Q, Feng J, Wu J, Yu Z, Zhang W, Chen Y, Yao P, Zhang H. HKDC1 C-terminal based peptides inhibit extranodal natural Killer\/T-cell lymphoma by modulation of mitochondrial function and EBV suppression. Leukemia. 2020;34(10):2736\u201348. https:\/\/doi.org\/10.1038\/s41375-020-0801-5.","journal-title":"Leukemia"},{"issue":"7","key":"1904_CR70","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3109\/07357900009032827","volume":"18","author":"AP Jillella","year":"2000","unstructured":"Jillella AP, Murren JR, Hamid KK, Longley BJ, Edelson RL, Cooper DL. P-Glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest. 2000;18(7):609\u201313. https:\/\/doi.org\/10.3109\/07357900009032827.","journal-title":"Cancer Invest"},{"key":"1904_CR71","doi-asserted-by":"publisher","first-page":"112435","DOI":"10.1016\/j.ejmech.2020.112435","volume":"200","author":"W Ali","year":"2020","unstructured":"Ali W, Spengler G, Kincses A, Nov\u00e9 M, Battistelli C, Latacz G, Starek M, D\u0105browska M, Honkisz-Orzechowska E, Romanelli A, Rasile MM, Szyma\u0144ska E, Jacob C, Zwergel C, Handzlik J. Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma. Eur J Med Chem. 2020;200:112435. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112435.","journal-title":"Eur J Med Chem"},{"key":"1904_CR72","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7722","author":"S Wu","year":"2020","unstructured":"Wu S, Zhang X, Dong M, Yang Z, Zhang M, Chen Q. sATP-binding Cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer\/T cell lymphoma side Population cells. Oncol Rep. 2020. https:\/\/doi.org\/10.3892\/or.2020.7722.","journal-title":"Oncol Rep"},{"key":"1904_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2606834","volume":"2018","author":"M Ni","year":"2018","unstructured":"Ni M, Qin B, Xie L, Zhang X, Yang J, Lv H, Yang M, Zhang M. IL-13 contributes to drug resistance of NK\/T-cell lymphoma cells by regulating ABCC4. Biomed Res Int. 2018;2018:1\u20139. https:\/\/doi.org\/10.1155\/2018\/2606834.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1904_CR74","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10637-022-01224-8","volume":"40","author":"J Huo","year":"2022","unstructured":"Huo J, Fu L, Jin M, Li Z, Zhang M. IL-10 contributes to gemcitabine resistance in extranodal NK\/T-cell lymphoma cells via ABCC4. Invest New Drugs. 2022;40(3):537\u201345. https:\/\/doi.org\/10.1007\/s10637-022-01224-8.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1904_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-019-0716-7","volume":"12","author":"S De Mel","year":"2019","unstructured":"De Mel S, Hue SS-S, Jeyasekharan AD, Chng W-J, Ng S-B. Molecular Pathogenic Pathways in Extranodal NK\/T Cell Lymphoma. J Hematol Oncol. 2019;12(1):33. https:\/\/doi.org\/10.1186\/s13045-019-0716-7.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1904_CR76","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","volume":"2","author":"GC Koo","year":"2012","unstructured":"Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh K-W, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Young Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST. Janus kinase 3\u2013activating mutations identified in natural killer\/T-cell lymphoma. Cancer Discov. 2012;2(7):591\u20137. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0028.","journal-title":"Cancer Discov"},{"issue":"1","key":"1904_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492835","volume":"49","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Li C, Xue W, Zhang M, Li Z. Frequent mutations in natural killer\/T cell lymphoma. Cell Physiol Biochem. 2018;49(1):1\u201316. https:\/\/doi.org\/10.1159\/000492835.","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"1904_CR78","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu Z-H, Yan Z-X, Zhao X, Xie Y-Y, Zhang Z-G, Pan C-M, Hu Y, Cai C-P, Dong Y, Huang J-Y, Wang L, Shen Y, Meng G, Zhou J-F, Hu J-D, Wang J-F, Liu Y-H, Yang L-H, Zhang F, Wang J-M, Wang Z, Peng Z-G, Chen F-Y, Sun Z-M, Ding H, Shi J-M, Hou J, Yan J-S, Shi J-Y, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao W-L, Chen Z, Chen S-J. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47(9):1061\u20136. https:\/\/doi.org\/10.1038\/ng.3358.","journal-title":"Nat Genet"},{"issue":"7","key":"1904_CR79","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-14-1216","volume":"21","author":"C K\u00fc\u00e7\u00fck","year":"2015","unstructured":"K\u00fc\u00e7\u00fck C, Hu X, Jiang B, Klinkebiel D, Geng H, Gong Q, Bouska A, Iqbal J, Gaulard P, McKeithan TW, Chan WC. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res. 2015;21(7):1699\u2013711. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1216.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1904_CR80","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","volume":"125","author":"Y-W Chen","year":"2015","unstructured":"Chen Y-W, Guo T, Shen L, Wong K-Y, Tao Q, Choi WWL, Au-Yeung RKH, Chan Y-P, Wong MLY, Tang JCO, Liu W-P, Li G-D, Shimizu N, Loong F, Tse E, Kwong Y-L, Srivastava G. Receptor-type tyrosine-protein phosphatase \u03ba directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma. Blood. 2015;125(10):1589\u2013600. https:\/\/doi.org\/10.1182\/blood-2014-07-588970.","journal-title":"Blood"},{"issue":"7","key":"1904_CR81","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","volume":"109","author":"PJ Jost","year":"2007","unstructured":"Jost PJ, Ruland J. Aberrant NF-\u03baB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7):2700\u20137. https:\/\/doi.org\/10.1182\/blood-2006-07-025809.","journal-title":"Blood"},{"key":"1904_CR82","doi-asserted-by":"crossref","unstructured":"Lv K, Li X, Yu H, Chen X, Zhang M, Wu X. Selection of new immunotherapy targets for NK\/T cell lymphoma. Am J Transl Res. 2020;12(11):7034\u201347.","DOI":"10.1186\/s13287-020-01909-y"},{"issue":"51","key":"1904_CR83","doi-asserted-by":"publisher","first-page":"35205","DOI":"10.1074\/jbc.M114.597187","volume":"289","author":"SM Wi","year":"2014","unstructured":"Wi SM, Moon G, Kim J, Kim S-T, Shim J-H, Chun E, Lee K-Y. TAK1-ECSIT-TRAF6 complex plays a key role in the TLR4 signal to activate NF-\u03baB. J Biol Chem. 2014;289(51):35205\u201314. https:\/\/doi.org\/10.1074\/jbc.M114.597187.","journal-title":"J Biol Chem"},{"key":"1904_CR84","doi-asserted-by":"publisher","unstructured":"Kimura, H. EBV in T-\/NK-Cell Tumorigenesis. In Human Herpesviruses; Kawaguchi, Y., Mori, Y., Kimura, H., Eds.; Advances in Experimental Medicine and Biology; Springer Singapore: ,2018; 1045: 459\u2013475. https:\/\/doi.org\/10.1007\/978-981-10-7230-7_21.","DOI":"10.1007\/978-981-10-7230-7_21"},{"issue":"4","key":"1904_CR85","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1046\/j.1365-2141.2001.02844.x","volume":"113","author":"M Uno","year":"2001","unstructured":"Uno M, Tsuchiyama J, Moriwaki A, Noguchi T, Mizoguchi K, Ogino T, Yoshino T, Okada S, Harada M. In Vitro induction of apoptosis for nasal Angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine a: drug resistance and apoptosis of NK-YS cell line. Br J Haematol. 2001;113(4):1009\u201314. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02844.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"1904_CR86","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2741\/4847","volume":"25","author":"R Nirmaladevi","year":"2020","unstructured":"Nirmaladevi R. Epigenetic Alterations in Cancer. Front Biosci. 2020;25(6):1058\u2013109. https:\/\/doi.org\/10.2741\/4847.","journal-title":"Front Biosci"},{"issue":"1","key":"1904_CR87","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","volume":"12","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang M. Epigenetic Alterations and Advancement of Treatment in Peripheral T-Cell Lymphoma. Clin Epigenet. 2020;12(1):169. https:\/\/doi.org\/10.1186\/s13148-020-00962-x.","journal-title":"Clin Epigenet"},{"key":"1904_CR88","doi-asserted-by":"publisher","first-page":"576391","DOI":"10.3389\/fcell.2020.576391","volume":"8","author":"I-C Chen","year":"2020","unstructured":"Chen I-C, Sethy B, Liou J-P. Recent update of HDAC inhibitors in lymphoma. Front Cell Dev Biol. 2020;8:576391. https:\/\/doi.org\/10.3389\/fcell.2020.576391.","journal-title":"Front Cell Dev Biol"},{"key":"1904_CR89","doi-asserted-by":"publisher","unstructured":"Lee, J.-H.; Choy, M. L.; Marks, P. A. Mechanisms of Resistance to Histone Deacetylase Inhibitors. In Advances in Cancer Research; Elsevier, 2012;116: 39\u201386. https:\/\/doi.org\/10.1016\/B978-0-12-394387-3.00002-1.","DOI":"10.1016\/B978-0-12-394387-3.00002-1"},{"issue":"6","key":"1904_CR90","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12185-022-03470-1","volume":"116","author":"M Yamagishi","year":"2022","unstructured":"Yamagishi M. The role of epigenetics in T-cell lymphoma. Int J Hematol. 2022;116(6):828\u201336. https:\/\/doi.org\/10.1007\/s12185-022-03470-1.","journal-title":"Int J Hematol"},{"issue":"01","key":"1904_CR91","doi-asserted-by":"publisher","first-page":"003","DOI":"10.1055\/s-0034-1397344","volume":"35","author":"A Mohr","year":"2015","unstructured":"Mohr A, Mott J. Overview of MicroRNA biology. Semin Liver Dis. 2015;35(01):003\u201311. https:\/\/doi.org\/10.1055\/s-0034-1397344.","journal-title":"Semin Liver Dis"},{"issue":"21","key":"1904_CR92","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-21-0573","volume":"27","author":"W Lone","year":"2021","unstructured":"Lone W, Bouska A, Sharma S, Amador C, Saumyaranjan M, Herek TA, Heavican TB, Yu J, Lim ST, Ong CK, Slack GW, Savage KJ, Rosenwald A, Ott G, Cook JR, Feldman AL, Rimsza LM, McKeithan TW, Greiner TC, Weisenburger DD, Melle F, Motta G, Pileri S, Vose JM, Chan WC, Iqbal J. Genome-wide miRNA expression profiling of molecular subgroups of peripheral T-cell lymphoma. Clin Cancer Res. 2021;27(21):6039\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0573.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1904_CR93","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/CBM-160126","volume":"18","author":"Y Lin","year":"2017","unstructured":"Lin Y, Chen W-M, Wang C, Chen X-Y. MicroRNA profiling in peripheral T-cell lymphoma not otherwise specified. CBM. 2017;18(4):339\u201347. https:\/\/doi.org\/10.3233\/CBM-160126.","journal-title":"CBM"},{"key":"1904_CR94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3389\/fonc.2019.00515","volume":"9","author":"M Mei","year":"2019","unstructured":"Mei M, Zhang M. Non-Coding RNAs in Natural Killer\/T-cell lymphoma. Front Oncol. 2019;9:515. https:\/\/doi.org\/10.3389\/fonc.2019.00515.","journal-title":"Front Oncol"},{"key":"1904_CR95","unstructured":"Saki N, Abroun S, Soleimani M, Hajizamani S, Shahjahani M, Kast RE, Mortazavi Y. Involvement of MicroRNA in T-Cell Differentiation and Malignancy. Int J Hematol Oncol Stem Cell Res. 2015;9(1):33\u201349."},{"issue":"1","key":"1904_CR96","doi-asserted-by":"publisher","first-page":"e29541","DOI":"10.1371\/journal.pone.0029541","volume":"7","author":"V Manf\u00e8","year":"2012","unstructured":"Manf\u00e8 V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, Lerche CM, Lauenborg BT, \u00d8dum N, Gniadecki R. miR-122 regulates P53\/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS One. 2012;7(1):e29541. https:\/\/doi.org\/10.1371\/journal.pone.0029541.","journal-title":"PLoS One"},{"issue":"15","key":"1904_CR97","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood-2009-06-222794","volume":"114","author":"Y Yamanaka","year":"2009","unstructured":"Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo Y-M, Iwamoto K, Yamashita J, Saitoh H, Kameoka Y, Shimizu N, Ichinohasama R, Sawada K. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma\/leukemia. Blood. 2009;114(15):3265\u201375. https:\/\/doi.org\/10.1182\/blood-2009-06-222794.","journal-title":"Blood"},{"issue":"5","key":"1904_CR98","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1155\/2010\/474692","volume":"29","author":"H-Q Guo","year":"2010","unstructured":"Guo H-Q, Huang G-L, Guo C-C, Pu X-X, Lin T-Y. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer\/T-cell lymphoma. Dis Markers. 2010;29(5):251\u20138. https:\/\/doi.org\/10.1155\/2010\/474692.","journal-title":"Dis Markers"},{"issue":"6","key":"1904_CR99","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.humpath.2012.08.023","volume":"44","author":"Y Xi","year":"2013","unstructured":"Xi Y, Li J, Zan L, Wang J, Wang G, Ning Y. Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma\/leukemia. Hum Pathol. 2013;44(6):1011\u20136. https:\/\/doi.org\/10.1016\/j.humpath.2012.08.023.","journal-title":"Hum Pathol"},{"issue":"12","key":"1904_CR100","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.3390\/cancers12123548","volume":"12","author":"KJ Ryu","year":"2020","unstructured":"Ryu KJ, Lee JY, Choi ME, Yoon SE, Cho J, Ko YH, Shim JH, Kim WS, Park C, Kim SJ. Serum-derived exosomal MicroRNA profiles can predict poor survival outcomes in patients with extranodal natural killer\/T-cell lymphoma. Cancers. 2020;12(12):3548. https:\/\/doi.org\/10.3390\/cancers12123548.","journal-title":"Cancers"},{"issue":"8","key":"1904_CR101","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14712598.2018.1499723","volume":"18","author":"S Viviani","year":"2018","unstructured":"Viviani S, Guidetti A. Efficacy of antibody-drug conjugate brentuximab vedotin in treating hodgkin\u2019s lymphoma. Expert Opin Biol Ther. 2018;18(8):841\u20139. https:\/\/doi.org\/10.1080\/14712598.2018.1499723.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1904_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-020-00603-3","volume":"16","author":"T Othman","year":"2021","unstructured":"Othman T, Herrera A, Mei M. Emerging therapies in relapsed and refractory Hodgkin lymphoma: what comes next after Brentuximab Vedotin and PD-1 inhibition? Curr Hematol Malig Rep. 2021;16(1):1\u20137. https:\/\/doi.org\/10.1007\/s11899-020-00603-3.","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"1904_CR103","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, Thomas SH, Forman SJ, Kane SE. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to Brentuximab Vedotin. Mol Cancer Ther. 2015;14(6):1376\u201384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0036.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1904_CR104","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","volume":"24","author":"NC Richardson","year":"2019","unstructured":"Richardson NC, Kasamon YL, Chen H, De Claro RA, Ye J, Blumenthal GM, Farrell AT, Pazdur R. FDA approval summary: Brentuximab Vedotin in first-line treatment of peripheral T-cell lymphoma. Oncologist. 2019;24(5):e180\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2019-0098.","journal-title":"Oncologist"},{"issue":"10168","key":"1904_CR105","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Ill\u00e9s \u00c1, Tobinai K, Tsukasaki K, Yeh S-P, Shustov A, H\u00fcttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Tr\u00fcmper L, Aboulafia D, Advani R, Alpdogan O, Ando K, Arcaini L, Baldini L, Bellam N, Bartlett N, Belada D, Yehuda DB, Benedetti F, Borchman P, Bordessoule D, Brice P, Briones J, Caballero D, Carella AM, Chang H, Cheong JW, Cho S-G, Choi I, Choquet S, Colita A, Congui AG, D\u2019amore F, Dang N, Davison K, De Guibert S, Brown PDN, Delwail V, Demeter J, Di Raimondo F, Do YR, Domingo E, Douvas M, Dreyling M, Ernst T, Fanale M, Fay K, Feldman T, Ferrero SF, Flinn IW, Forero-Torres A, Fox C, Friedberg J, Fukuhara N, Garcia-Marco J, Cruz JG, Codina JG, Gressin R, Grigg A, Gurion R, Christensen JH, Haioun C, Hajek R, Hanel M, Hatake K, Hensen R, Horowitz N, Horwitz S, Huttmann A, Illes A, Illidge T, Ishizawa K, Islas-Ohlmayer M, Jacobsen E, Janakiram M, Jurczak W, Kaminski M, Kato K, Kim WS, Kirgner I, Iyer S, Kuo C-Y, Lazaroiu MC, Du KL, Lee J-S, LeGouill S, Lennard A, LaRosee P, Levi I, Link B, Maisonneuve H, Maruyama D, Mayer J, McCarty J, McKay P, Minami Y, Mocikova H, Morra E, Morschhauser F, Munoz J, Nagai H, O\u2019Connor O, Opat S, Pettengell R, Pezzutto A, Pfreundschuh M, Pluta A, Porcu P, Pro B, Quach H, Rambaldi A, Renwick W, Reyes R, Izquierdo AR, Rossi G, Ruan J, Rusconi C, Salles G, Santoro A, Sarriera J, Savage K, Shibayama H, Shustov A, Suh C, Sureda A, Tanimoto M, Taniwaki M, Tilly H, Tobinai K, Trneny M, Trumper L, Tsukamoto N, Tsukasaki K, Vitolo U, Walewski J, Weidmann E, Wilhelm M, Witzens-Harig M, Yacoub A, Yamamoto K, Yeh S-P, Yoon S-S, Yuen S, Yun HJ, Zain J, Zinzani PL. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"issue":"4","key":"1904_CR106","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","volume":"50","author":"HK Kim","year":"2015","unstructured":"Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS. Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with Brentuximab Vedotin. Blood Res. 2015;50(4):254. https:\/\/doi.org\/10.5045\/br.2015.50.4.254.","journal-title":"Blood Res"},{"issue":"3","key":"1904_CR107","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Ill\u00e9s \u00c1, Tobinai K, Tsukasaki K, Yeh S-P, Shustov A, H\u00fcttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. The ECHELON-2 trial: 5-Year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002.","journal-title":"Ann Oncol"},{"issue":"4","key":"1904_CR108","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0093-7754(03)00261-6","volume":"30","author":"N Villamor","year":"2003","unstructured":"Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003;30(4):424\u201333. https:\/\/doi.org\/10.1016\/S0093-7754(03)00261-6.","journal-title":"Semin Oncol"},{"key":"1904_CR109","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fphar.2019.00749","volume":"10","author":"P Liu-Kreyche","year":"2019","unstructured":"Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-Gp-MDR1 confers drug resistance of Brentuximab Vedotin and its cytotoxic payload monomethyl Auristatin E in tumor cells. Front Pharmacol. 2019;10:749. https:\/\/doi.org\/10.3389\/fphar.2019.00749.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1904_CR110","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/his.13002","volume":"69","author":"V Mehra","year":"2016","unstructured":"Mehra V, Pomplum S, Ireland R, Yallop D, Devereux S, Marcus R, Shah C, Patten P, Kassam S. ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to Brentuximab and Crizotinib. Histopathology. 2016;69(5):880\u20132. https:\/\/doi.org\/10.1111\/his.13002.","journal-title":"Histopathology"},{"issue":"5","key":"1904_CR111","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman SJ, Kwak LW, Rosen ST, Newman EM. Inhibition of MDR1 overcomes resistance to Brentuximab Vedotin in Hodgkin lymphoma. Clin Cancer Res. 2020;26(5):1034\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1768.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1904_CR112","doi-asserted-by":"publisher","first-page":"68","DOI":"10.18773\/austprescr.2019.020","volume":"42","author":"New Drug","year":"2019","unstructured":"New Drug. Pralatrexate for Lymphoma. Aust Prescr. 2019;42(2):68. https:\/\/doi.org\/10.18773\/austprescr.2019.020.","journal-title":"Aust Prescr"},{"issue":"9","key":"1904_CR113","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Jo Lechowicz M, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. JCO. 2011;29(9):1182\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.9024.","journal-title":"JCO"},{"key":"1904_CR114","doi-asserted-by":"publisher","unstructured":"Advani, R. H.; Ansell, S. M.; Lechowicz, M. J.; Beaven, A. W.; Loberiza, F.; Carson, K. R.; Evens, A. M.; Foss, F.; Horwitz, S.; Pro, B.; Pinter-Brown, L. C.; Smith, S. M.; Shustov, A. R.; Savage, K. J.; M. Vose, J. A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating with Pralatrexate (P) as Front Line Therapy for Patients with Peripheral T-Cell Lymphoma (PTCL): Final Results from the T- Cell Consortium Trial. Br J Haematol 2016, 172 (4), 535\u2013544. https:\/\/doi.org\/10.1111\/bjh.13855.","DOI":"10.1111\/bjh.13855"},{"issue":"4","key":"1904_CR115","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/14656566.2013.770474","volume":"14","author":"A Shimanovsky","year":"2013","unstructured":"Shimanovsky A, Dasanu CA. Pralatrexate\u202f: evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother. 2013;14(4):515\u201323. https:\/\/doi.org\/10.1517\/14656566.2013.770474.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1904_CR116","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1186\/s12885-021-08607-9","volume":"21","author":"K Oiwa","year":"2021","unstructured":"Oiwa K, Hosono N, Nishi R, Scotto L, O\u2019Connor OA, Yamauchi T. Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance. BMC Cancer. 2021;21(1):879. https:\/\/doi.org\/10.1186\/s12885-021-08607-9.","journal-title":"BMC Cancer"},{"issue":"9","key":"1904_CR117","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","volume":"21","author":"S Jain","year":"2015","unstructured":"Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O\u2019Connor OA. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21(9):2096\u2013106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2249.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1904_CR118","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","volume":"16","author":"E Marchi","year":"2010","unstructured":"Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O\u2019Connor OA. Pralatrexate is synergistic with the proteasome inhibitor Bortezomib in In Vitro and In Vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010;16(14):3648\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0671.","journal-title":"Clin Cancer Res"},{"key":"1904_CR119","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2021.06.059","volume":"164","author":"C Rossi","year":"2022","unstructured":"Rossi C, Casasnovas R-O. PD-1 Inhibitors in patients with hodgkin lymphoma. Eur J Cancer. 2022;164:114\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.059.","journal-title":"Eur J Cancer"},{"key":"1904_CR120","doi-asserted-by":"publisher","first-page":"105999","DOI":"10.1016\/j.intimp.2019.105999","volume":"77","author":"M Xie","year":"2019","unstructured":"Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol. 2019;77:105999. https:\/\/doi.org\/10.1016\/j.intimp.2019.105999.","journal-title":"Int Immunopharmacol"},{"key":"1904_CR121","doi-asserted-by":"publisher","first-page":"107870","DOI":"10.1016\/j.intimp.2021.107870","volume":"98","author":"M Jalili-Nik","year":"2021","unstructured":"Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H, Hashemy SI. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell leukemia\/lymphoma. Int Immunopharmacol. 2021;98:107870. https:\/\/doi.org\/10.1016\/j.intimp.2021.107870.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1904_CR122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1411087.","journal-title":"N Engl J Med"},{"issue":"2","key":"1904_CR123","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1097\/HS9.0000000000000672","volume":"6","author":"R Houot","year":"2022","unstructured":"Houot R, Poeschel V, Altmann B, Angel S, Thurner L, Illmer T, Andre M, Dreyling M, Maisonneuve H, Tilly H, Mayer S, Casasnovas O, Le Gouill S, Offner F, Cartron G, Kerkhoff A, Weber T, Hoffmann J, Ziepert M, Klapper W, Itti E, Hellwig D, Natchkebia G, De Leval L, Rosenwald A, Haioun C, Dercle L, Gaulard P, Held G. Prolonged remissions after nivolumab plus gemcitabine\/Oxaliplatin in relapsed\/refractory T-cell lymphoma. HemaSphere. 2022;6(2):e672. https:\/\/doi.org\/10.1097\/HS9.0000000000000672.","journal-title":"HemaSphere"},{"issue":"17","key":"1904_CR124","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"Y-L Kwong","year":"2017","unstructured":"Kwong Y-L, Chan TSY, Tan D, Kim SJ, Poon L-M, Mow B, Khong P-L, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-Asparaginase. Blood. 2017;129(17):2437\u201342. https:\/\/doi.org\/10.1182\/blood-2016-12-756841.","journal-title":"Blood"},{"issue":"1","key":"1904_CR125","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH. Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15. https:\/\/doi.org\/10.1186\/s13045-018-0559-7.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1904_CR126","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TCC, Chiu JW, Tse E, Kwong Y-L. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777\u201389. https:\/\/doi.org\/10.1080\/21645515.2016.1199310.","journal-title":"Hum Vaccin Immunother"},{"key":"1904_CR127","doi-asserted-by":"publisher","first-page":"869488","DOI":"10.3389\/fphar.2022.869488","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Wu W, Wei W, Zou L. Immune checkpoint inhibitors in peripheral T-cell lymphoma. Front Pharmacol. 2022;13:869488. https:\/\/doi.org\/10.3389\/fphar.2022.869488.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1904_CR128","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3390\/ijms21072356","volume":"21","author":"A Von Knethen","year":"2020","unstructured":"Von Knethen A, Heinicke U, Weigert A, Zacharowski K, Br\u00fcne B. Histone deacetylation inhibitors as modulators of regulatory T cells. IJMS. 2020;21(7):2356. https:\/\/doi.org\/10.3390\/ijms21072356.","journal-title":"IJMS"},{"key":"1904_CR129","doi-asserted-by":"publisher","unstructured":"Zahnow, C. A.; Topper, M.; Stone, M.; Murray-Stewart, T.; Li, H.; Baylin, S. B.; Casero, R. A. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation. In Advances in Cancer Research; Elsevier, 2016; 130: 55\u2013111. https:\/\/doi.org\/10.1016\/bs.acr.2016.01.007.","DOI":"10.1016\/bs.acr.2016.01.007"},{"issue":"13","key":"1904_CR130","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2146\/ajhp120163","volume":"70","author":"AL McGraw","year":"2013","unstructured":"McGraw AL. Romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm. 2013;70(13):1115\u201322. https:\/\/doi.org\/10.2146\/ajhp120163.","journal-title":"Am J Health Syst Pharm"},{"issue":"16","key":"1904_CR131","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O\u2019Connor OA. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370. https:\/\/doi.org\/10.1182\/blood.2020009004.","journal-title":"Blood"},{"issue":"9","key":"1904_CR132","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","volume":"20","author":"SP Iyer","year":"2015","unstructured":"Iyer SP, Foss FF. Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist. 2015;20(9):1084\u201391. https:\/\/doi.org\/10.1634\/theoncologist.2015-0043.","journal-title":"Oncologist"},{"issue":"3","key":"1904_CR133","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, Andr\u00e9 M, Garc\u00eda-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, H\u00fcttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue M-H, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA). J Clin Oncol. 2022;40(3):242\u201351. https:\/\/doi.org\/10.1200\/JCO.21.01815.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1904_CR134","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1078155216634178","volume":"23","author":"P Campbell","year":"2017","unstructured":"Campbell P, Thomas CM. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. J Oncol Pharm Pract. 2017;23(2):143\u20137. https:\/\/doi.org\/10.1177\/1078155216634178.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1904_CR135","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1904_CR136","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3892\/ol.2014.2714","volume":"9","author":"X Ni","year":"2015","unstructured":"Ni X, Li L, Pan G. HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review). Oncol Lett. 2015;9(2):515\u201321. https:\/\/doi.org\/10.3892\/ol.2014.2714.","journal-title":"Oncol Lett"},{"issue":"1","key":"1904_CR137","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41419-022-04508-2","volume":"13","author":"J Bi","year":"2022","unstructured":"Bi J, Zhang Y, Malmrose PK, Losh HA, Newtson AM, Devor EJ, Thiel KW, Leslie KK. Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer. Cell Death Dis. 2022;13(1):59. https:\/\/doi.org\/10.1038\/s41419-022-04508-2.","journal-title":"Cell Death Dis"},{"key":"1904_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7350489","volume":"2022","author":"Z Peng","year":"2022","unstructured":"Peng Z, Xiong J, Dong H. Valproic acid inhibits peripheral T cell lymphoma cells behaviors via restraining PI3K\/AKT pathway. Evid Based Complementa Altern Med. 2022;2022:1\u20139. https:\/\/doi.org\/10.1155\/2022\/7350489.","journal-title":"Evid Based Complementa Altern Med"},{"issue":"1","key":"1904_CR139","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13046-017-0639-5","volume":"37","author":"SJ Wu","year":"2018","unstructured":"Wu SJ, Chen J, Wu B, Wang YJ, Guo KY. MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK\/T cell lymphoma. J Exp Clin Cancer Res. 2018;37(1):18. https:\/\/doi.org\/10.1186\/s13046-017-0639-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"1904_CR140","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888\u201398. https:\/\/doi.org\/10.1182\/blood-2017-08-802470.","journal-title":"Blood"},{"issue":"4","key":"1904_CR141","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.16435","volume":"189","author":"D Huang","year":"2020","unstructured":"Huang D, Song TL, Nairism\u00e4gi M, Laurensia Y, Pang W, Zhe DCM, Wong EKY, Wijaya GG, Tan J, Tan SH, Lim J, Chia BKH, Chan JY, Tang TPL, Somasundaram N, Cheng CL, Politz O, Liu N, Lim ST, Ong CK. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma. Br J Haematol. 2020;189(4):731\u201344. https:\/\/doi.org\/10.1111\/bjh.16435.","journal-title":"Br J Haematol"},{"issue":"18","key":"1904_CR142","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Copanlisib: first global approval. Drugs. 2017;77(18):2057\u201362. https:\/\/doi.org\/10.1007\/s40265-017-0838-6.","journal-title":"Drugs"},{"issue":"12","key":"1904_CR143","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1517\/13543784.2014.972501","volume":"23","author":"D Alrifai","year":"2014","unstructured":"Alrifai D, Pettengell R. MLN8237 (Alisertib) and its role in peripheral T-cell lymphoma. Expert Opin Investig Drugs. 2014;23(12):1731\u20136. https:\/\/doi.org\/10.1517\/13543784.2014.972501.","journal-title":"Expert Opin Investig Drugs"},{"issue":"18","key":"1904_CR144","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","volume":"21","author":"KM Zullo","year":"2015","unstructured":"Zullo KM, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto L, Amengual JE, Mao Y, Nandakumar R, Cremers S, Duong J, Mahadevan D, O\u2019Connor OA. Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res. 2015;21(18):4097\u2013109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0033.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1904_CR145","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1158\/1078-0432.CCR-12-0571","volume":"18","author":"A Cervantes","year":"2012","unstructured":"Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Rosell\u00f3 S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Ma\u00f1os L, P\u00e9rez-Fidalgo J-A, Fingert H, Baselga J, Tabernero J. Phase I Pharmacokinetic\/pharmacodynamic study of MLN8237, an investigational, oral, selective Aurora A kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(17):4764\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0571.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1904_CR146","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12185-023-03573-3","volume":"117","author":"K Ishitsuka","year":"2023","unstructured":"Ishitsuka K. T cell lymphoma: time to make discoveries and advance treatment. Int J Hematol. 2023;117(4):473\u20134. https:\/\/doi.org\/10.1007\/s12185-023-03573-3.","journal-title":"Int J Hematol"},{"issue":"8","key":"1904_CR147","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajh.26270","volume":"96","author":"JM Zain","year":"2021","unstructured":"Zain JM, Hanona P. Aggressive T-cell Lymphomas: 2021 updates on diagnosis, risk stratification and management. Am J Hematol. 2021;96(8):1027\u201346. https:\/\/doi.org\/10.1002\/ajh.26270.","journal-title":"Am J Hematol"},{"key":"1904_CR148","doi-asserted-by":"publisher","unstructured":"Chamuleau ED, Van De Loosdrecht MA, Huijgens PC. Monoclonal antibody therapy in haematological malignancies. CCP. 2010;5(3);148\u201359. https:\/\/doi.org\/10.2174\/157488410791498752.","DOI":"10.2174\/157488410791498752"},{"key":"1904_CR149","doi-asserted-by":"publisher","first-page":"100889","DOI":"10.1016\/j.blre.2021.100889","volume":"52","author":"A Mina","year":"2022","unstructured":"Mina A, Pro B. T time: emerging and new therapies for peripheral T-cell lymphoma. Blood Rev. 2022;52:100889. https:\/\/doi.org\/10.1016\/j.blre.2021.100889.","journal-title":"Blood Rev"},{"key":"1904_CR150","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753.","journal-title":"Pharmacol Ther"},{"key":"1904_CR151","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.drup.2020.100715","volume":"53","author":"N Erin","year":"2020","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updates. 2020;53:100715. https:\/\/doi.org\/10.1016\/j.drup.2020.100715.","journal-title":"Drug Resist Updates"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01904-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01904-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01904-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:03:10Z","timestamp":1704337390000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01904-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1904"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01904-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"24 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}